Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels

Rían W. Manville and Geoffrey W. Abbott
Molecular Pharmacology October 2018, 94 (4) 1155-1163; DOI: https://doi.org/10.1124/mol.118.112953
Rían W. Manville
Bioelectricity Laboratory, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoffrey W. Abbott
Bioelectricity Laboratory, Department of Physiology and Biophysics, School of Medicine, University of California, Irvine, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Fig. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 1.

    KCNQ3 contains a conserved neurotransmitter binding pocket. (A) Topological representation of KCNQ3 showing two of the four subunits, without domain swapping for clarity. Pentagon, approximate position of KCNQ3-W265; VSD, voltage-sensing domain. (B) Chimeric KCNQ1/KCNQ3structural model (red, KCNQ3-W265). Domain coloring as in (A). (C and D) Close-up side views of KCNQ structure as in (B), showing results of SwissDock.

  • Fig. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 2.

    Gabapentin is predicted to bind to KCNQ3-W265. (A) Electrostatic surface potentials (red, electron-dense; blue, electron-poor; green, neutral) and structures calculated and plotted using Jmol. (B and C) Long-range (B) and close-up (C) side views of KCNQ1/3 chimera model structure showing results of SwissDock unguided in silico docking of gabapentin. Domain colors as in Fig. 1.

  • Fig. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 3.

    Gabapentin is a potent activator of heteromeric KCNQ2/3 potassium channels. (A) Left, mean two-electrode voltage-clamp (TEVC) traces for KCNQ2/3 expressed in Xenopus oocytes in the absence (control) or presence of 10 nM gabapentin (n = 7 to 8). Dashed line here and throughout, zero current level. Right, voltage protocol. (B) Mean tail current and normalized tail currents (G/Gmax) vs. prepulse voltage relationships recorded by TEVC in Xenopus oocytes expressing KCNQ2/3 channels in the absence (black) or presence (red) of 10 nM or 1 µM gabapentin as indicated (n = 7 to 8). Error bars indicate S.D. Voltage protocol as in (A). (C) Mean TEVC traces for KCNQ2/3 expressed in Xenopus oocytes in the absence (control) or presence of 1 µM pregabalin (n = 7 to 8). Lower inset, voltage protocol. (D) Mean tail current and normalized tail currents (G/Gmax) vs. prepulse voltage relationships recorded by TEVC in Xenopus oocytes expressing KCNQ2/3 channels in the absence (black) or presence (blue) of 1 µM pregabalin as indicated (n = 5). Error bars indicate S.D. Voltage protocol as in (C). (E) Voltage dependence of KCNQ2/3 current fold increase by gabapentin vs. pregabalin (10 nM), plotted from traces as in (A and C) (n = 5–8). Error bars indicate S.D. *P < 0.05 vs. pregabalin current at −60 mV. (F) Gabapentin and pregabalin dose responses at −60 mV for KCNQ2/3 activation, quantified from data as in (A–E) (n = 7 to 8). Error bars indicate S.D. (G) Dose response for gabapentin and pregabalin effects on resting membrane potential (EM) of unclamped oocytes expressing KCNQ2/3 (n = 7 to 8). Error bars indicate S.D. (H) Mean tail current vs. prepulse voltage relationships recorded by TEVC in Xenopus oocytes expressing KCNQ2/3 channels in the absence (black) or presence (green) of 30 µM retigabine as indicated (n = 4). Error bars indicate S.D. Voltage protocol as in (A). (I) Voltage dependence of KCNQ2/3 current fold increase by retigabine (30 µM), n = 4). Error bars indicate S.D. (J) Retigabine dose responses at −60 mV for KCNQ2/3 activation, quantified from data as in (A–E) (n = 4). Ctrl, control. Error bars indicate S.D.

  • Fig. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 4.

    Gabapentin-activated current is XE991 sensitive and exhibits altered gating kinetics. (A) Exemplar −60 mV KCNQ2/3 current before (left, black), during wash-in of gabapentin (red) and partial washout with bath solution in the absence of drug (black), and then wash-in of XE991 (blue). (B and C) Mean activation at +40 mV (B) and deactivation at −80 mV (C) rates for KCNQ2/3 before (control) and after wash-in of 1 µM gabapentin (GABAP) (n = 7). Activation rate was quantified using the voltage protocol as in Fig. 3A. Deactivation rate was quantified using the voltage protocol shown here. Error bars indicate S.D.

  • Fig. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 5.

    Gabapentin is a potent activator of homomeric KCNQ3 and KCNQ5 potassium channels. (A) Mean two-electrode voltage-clamp (TEVC) traces for homomeric KCNQ2, 3*, 4, or 5 channels (as indicated) expressed in Xenopus oocytes in the absence (control) or presence of 1 µM gabapentin (n = 4–8). Voltage protocol, upper inset. (B) Mean tail current (left) and normalized tail currents (G/Gmax; right) vs. prepulse voltage relationships recorded by TEVC in Xenopus oocytes expressing homomeric KCNQ2, 3*, 4, or 5 channels (as indicated) in the absence (black) or presence (red) of 1 µM gabapentin as indicated (n = 4–8). Error bars indicate S.D. (C) Voltage dependence of current fold increase by gabapentin (1 µM) for homomeric KCNQ2, 3*, 4, or 5 channels, plotted from traces as in (A) (n = 4–8). Error bars indicate S.D. (D) Gabapentin dose responses at −60 mV for homomeric KCNQ2, 3*, 4, or 5 channel activation, quantified from data as in (A) (n = 4–8). Ctrl, control. Error bars indicate S.D.

  • Fig. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Fig. 6.

    Gabapentin activation of KCNQ2/3 requires KCNQ3-W265. (A–C) Two-electrode voltage-clamp (TEVC) of water-injected Xenopus laevis oocytes showing no effect of gabapentin (10 nM) on endogenous currents or membrane potential (EM) (n = 5). (A) Mean traces; (B) mean peak current; (C) mean EM, in the absence (control) or presence of 10 nM gabapentin. Voltage protocol (A, upper inset). Error bars indicate S.D. (D and E) TEVC of Xenopus laevis oocytes showing effects of gabapentin (10 nM) on heteromeric KCNQ2/KCNQ3-W265L channels. (D) Mean traces; (E) mean tail current (left) and mean normalized tail current (G/Gmax; right). n = 5. Error bars indicate S.D. (F and G) TEVC of Xenopus laevis oocytes showing effects of gabapentin (10 nM) on heteromeric KCNQ2-W236L/KCNQ3-W265L channels. (F) Mean traces; (G) mean tail current (left) and mean normalized tail current (G/Gmax; right); n = 5. Error bars indicate S.D. (H) Mean tail current fold changes vs. prepulse voltages for channels as indicated; KCNQ2/KCNQ3 results (black line) from Fig. 3E shown for comparison; n = 5. Error bars indicate S.D. *P < 0.05 vs. other groups at −60 mV. (I) Mean dose responses for channels as indicated; KCNQ2/KCNQ3 results (black line) from Fig. 3F shown for comparison; n = 5. Error bars indicate S.D.

Additional Files

  • Figures
  • Data Supplement

    • Supplemental Data -

      Supplementary Figure 1 - Effects of Gabapentin on KCNQ2/3 channels

      Supplementary Table 1 - Summary of Effects of Gabapentin on KCNQ2/3 channels. Statistics

      Supplementary Figure 2 - Effects of Pregabalin on KCNQ2/3 channels

      Supplementary Table 2 - Summary of Effects of Pregabalin on KCNQ2/3 channels

      Supplementary Figure 3 - Effects of retigabine on KCNQ2/3 channels

      Supplementary Table 3 - Summary of Effects of retigabine on KCNQ2/3 channels

      Supplementary Figure 4 - Effects of Gabapentin on KCNQ2 channels

      Supplementary Table 4 - Summary of Effects of Gabapentin on KCNQ2 channels

      Supplementary Figure 5 - Effects of Gabapentin on KCNQ3* channels

      Supplementary Table 5 - Summary of Effects of Gabapentin on KCNQ3* channels

      Supplementary Figure 6 - Effects of Gabapentin on KCNQ4 channels

      Supplementary Table 6 - Summary of Effects of Gabapentin on KCNQ4 channels

      Supplementary Figure 7 - Effects of Gabapentin on KCNQ5 channels

      Supplementary Table 7 - Summary of Effects of Gabapentin on KCNQ5 channels

      Supplementary Figure 8 - Effects of Gabapentin on KCNQ2/KCNQ3-W265L channels

      Supplementary Table 8 - Summary of Effects of Gabapentin on KCNQ2/KCNQ3-W265L channels

      Supplementary Figure 9 - Effects of Gabapentin on KCNQ2-W236L/KCNQ3-W265L channels

      Supplementary Table 9 - Summary of Effects of Gabapentin on KCNQ2-W236L/KCNQ3-W265L channels

PreviousNext
Back to top

In this issue

Molecular Pharmacology: 94 (4)
Molecular Pharmacology
Vol. 94, Issue 4
1 Oct 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Gabapentin Is a Potent Activator of KCNQ3 and KCNQ5 Potassium Channels
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Gabapentin Activates KCNQ Channels

Rían W. Manville and Geoffrey W. Abbott
Molecular Pharmacology October 1, 2018, 94 (4) 1155-1163; DOI: https://doi.org/10.1124/mol.118.112953

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Gabapentin Activates KCNQ Channels

Rían W. Manville and Geoffrey W. Abbott
Molecular Pharmacology October 1, 2018, 94 (4) 1155-1163; DOI: https://doi.org/10.1124/mol.118.112953
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of Celecoxib targets by label-free TPP
  • Editing TOP2α Intron 19 5′ SS Circumvents Drug Resistance
  • CTS Bias
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics